- Home
- NMS vs INO Comparison
NMS vs INO Comparison
Compare NMS & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- INO
- Stock Information
- Founded
- NMS 1993
- INO 1979
- Country
- NMS United States
- INO United States
- Employees
- NMS N/A
- INO N/A
- Industry
- NMS Finance Companies
- INO Medical/Dental Instruments
- Sector
- NMS Finance
- INO Health Care
- Exchange
- NMS Nasdaq
- INO Nasdaq
- Market Cap
- NMS 71.2M
- INO 69.3M
- IPO Year
- NMS N/A
- INO 1998
- Fundamental
- Price
- NMS $11.81
- INO $2.30
- Analyst Decision
- NMS
- INO Buy
- Analyst Count
- NMS 0
- INO 5
- Target Price
- NMS N/A
- INO $8.80
- AVG Volume (30 Days)
- NMS 12.0K
- INO 2.1M
- Earning Date
- NMS 01-01-0001
- INO 11-13-2025
- Dividend Yield
- NMS 4.11%
- INO N/A
- EPS Growth
- NMS N/A
- INO N/A
- EPS
- NMS N/A
- INO N/A
- Revenue
- NMS N/A
- INO $182,337.00
- Revenue This Year
- NMS N/A
- INO N/A
- Revenue Next Year
- NMS N/A
- INO $15,960.33
- P/E Ratio
- NMS N/A
- INO N/A
- Revenue Growth
- NMS N/A
- INO N/A
- 52 Week Low
- NMS $9.21
- INO $1.30
- 52 Week High
- NMS $12.18
- INO $7.00
- Technical
- Relative Strength Index (RSI)
- NMS 71.01
- INO 52.81
- Support Level
- NMS $11.68
- INO $2.16
- Resistance Level
- NMS $11.87
- INO $2.98
- Average True Range (ATR)
- NMS 0.11
- INO 0.20
- MACD
- NMS 0.04
- INO -0.07
- Stochastic Oscillator
- NMS 89.26
- INO 20.12
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.